Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

123Citations
Citations of this article
126Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF, DM, or CKD. Methods: MEDLINE, EMBASE, and ClinicalTrials.gov were searched from inception up to 27 August 2020. Randomized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo were included. The outcomes of interest include atrial fibrillation (AF), embolic stroke, atrial flutter (AFL), AF/AFL, ventricular tachycardia (VT), and cardiac arrest. Relative risks (RRs) and 95% confidence intervals (CI) were pooled using a random-effects model. Results: Out of 4,532 citations, 22 trials with altogether 52,115 patients were included (mean age 63.2 years; 33,747 [64.8%] of participants were men). SGLT2i were associated with a lower risk of AF (RR 0.82, 95% CI 0.70–0.96), embolic stroke (RR 0.32, 95% CI 0.12–0.85), AF/AFL (RR 0.82, 95% CI 0.71–0.95), and VT (RR 0.73, 95% CI 0.53–0.99), while the risk reductions in AFL (RR 0.83, 95% CI 0.58–1.17) and cardiac arrest (RR 0.83, 95% CI 0.61–1.14) did not reach statistical significance. The associations appeared to be consistent across different baseline conditions (DM vs CKD vs HF; atherosclerotic cardiovascular disease [ASCVD] vs no ASCVD) and the SGLT2i used. Conclusions: SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.

References Powered by Scopus

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

42310Citations
N/AReaders
Get full text

Cochrane handbook for systematic reviews of interventions

36061Citations
N/AReaders
Get full text

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

25303Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

161Citations
N/AReaders
Get full text

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

155Citations
N/AReaders
Get full text

The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review

106Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, H. L., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y. K., Wu, M. zhen, … Yiu, K. H. (2021). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovascular Diabetology, 20(1). https://doi.org/10.1186/s12933-021-01293-8

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

55%

Researcher 11

35%

Lecturer / Post doc 2

6%

Professor / Associate Prof. 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 44

75%

Pharmacology, Toxicology and Pharmaceut... 6

10%

Social Sciences 5

8%

Nursing and Health Professions 4

7%

Save time finding and organizing research with Mendeley

Sign up for free